From: A lipidomic approach to the study of human CD4+ T lymphocytes in multiple sclerosis
m/z value | Assignment [M-H]− | m/z value | Assignment [M-H]− |
---|---|---|---|
513,400 | Matrix | 799,767 | SM d17:1/24:0 or d18:1/23:0 |
529,389 | Matrix | 800,596 | PE 41:0 or PS 37:2 |
573,412 | Matrix | 802,607 | PE 42:6 or PS 38:1 |
617,430 | Matrix | 806,584 | PE 42:4 |
618,557 | Matrix | 808,601 | PE 41:4 or PS 38:5 |
619,371 | PA 30:0 | 826,604 | PE 42:2 |
666,141 | Matrix | 828,631 | PE 42:1 |
687,632 | DG 41:3 | 836,632 | PE 43.4 or PS 40:5 |
722,603 | PE 36:4 | 850,617 | PE 44:4 or PS 42:4 |
738,599 | Sphyngolipid 15:2/22:0 | 852,631 | PE 44:3 |
742,634 | PE 36:2 | 857,625 | PG 42:2 |
743,696 | SM 37:1 | 859,642 | PI 36:2 |
744,652 | PE 36:1 | 861,640 | PG 42:0 or PI 36:2 |
746,600 | PE 36:0 | 883,642 | PI 38:5 |
750,636 | Sphyngolipid 18:2/20:1 | 885,661 | PG 44:2 |
760,934 | PE O-38:0 | 901,657 | PI 40:2 |
764,619 | PE 38:5 | 909,663 | PI 40:6 |
766,634 | Sphyngolipid 18:2/21:0 | 911,618 | PI 40:6 |
769,716 | PA 42:1 or SM 39:0 | 913,696 | PI 40:4 |
771,732 | PA 42:0 or SM 38:1 | 943,623 | PI 42:3 |
776,849 | PE O-40:6 or PS O-36:0 | 1.448,140 | CL 72:8 |
778,651 | PE 40:4 | 1.470,150 | CL 74:11 |
780,560 | PE 41:4 | 1.472,170 | CL 74:10 |
782,562 | PE 41:3 | 1.494,150 | CL 75:6 |
792,650 | PE 40:5 | 1.496,170 | CL 75:5 |
794,675 | Sphingolipid 18:2/23:0 | 1.498,190 | CL 75:4 |
795,736 | PI O-32:0 | ||
797,754 | SM d17/24:1 |